Pembrolizumab Biosimilar - Anti-PD1 mAb - Research Grade
Source
DrugBank DB09037
Species
Human
Molecular weight
149kDa
Purity
>85%
Buffer
PBS pH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
Pembrolizumab,Pembrolizumab,PD1,anti-PD1
Reference
PX-TA1007
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG4
Clonality
Monoclonal Antibody
Description of Pembrolizumab Biosimilar - Anti-PD1 mAb - Research Grade
General information about Pembrolizumab
Pembrolizumab is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It works by targeting the cellular pathway of proteins found on the body’s immune cells and some cancer cells, known as PD-1/PD-L1. This product is for research use only.
Reviews
There are no reviews yet.